BVF.SG - BAUSCH HEALTH COS INC
| Previous Close | 20.28 |
| Open | 19.24 |
| Bid | 0.00 x 100000 |
| Ask | 0.00 x 100000 |
| Day's Range | 19.24 - 19.36 |
| 52 Week Range | 9.45 - 23.17 |
| Volume | 130 |
| Avg. Volume | 511 |
| Market Cap | N/A |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals•last month
What Cindy Eckert has planned with Sprout, Addyi back in hands
It’s take two for Sprout Pharmaceuticals and Addyi, the only drug approved by the U.S. Food and Drug Administration to treat low sexual desire disorder (HSDD) in women.
- Market Realist•last month
Analysts’ Recommendations for Valeant in June
Valeant Pharmaceuticals (VRX) is one of the pharmaceutical companies that’s focused on developing and commercializing prescription pharmaceuticals, generic pharmaceuticals, over-the-counter products, and eye care products. Wall Street analysts expect revenues of ~$2.1 billion during the second quarter.
- Reuters•2 months ago
Morning News Call Canadienne - Mai 8
Pour consulter la lettre d'information; cliquez sur le lien: http://share.thomsonreuters.com/assets/newsletters/Morning_News_Call/MNCCA_FR_05082018.pdf PRINCIPAUX INDICATEURS À L’AGENDA 08:15 Mises en ...
- InvestorPlace•3 months ago
Allergan plc Stock Looks Cheap for Good Reasons
From a headline standpoint, Allergan plc (NYSE:AGN) stock does look attractive at the moment. A steady pullback has seen Allergan stock fall about 35% from late July highs and Allergan has dropped by half from 2015 levels. A sub-10x forward EPS multiple is notably cheaper than those assigned to rivals like Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK).
- InvestorPlace•4 months ago
5 Big Biotech Stocks to Buy Under $10
For investors, biotech stocks remain one of the most dynamic sectors out there. On one hand, you have some of the largest pharmaceutical firms on the planet with multi-billion-dollar blockbuster drugs filling their coffers. On the other, you have the more stereotypical “lotto ticket” biotech stocks of clinical or early production stage firms.
InvestorPlace•4 months agoHow Valeant Pharmaceuticals Intl Inc Can Give You a 750% Return
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) still has its share of detractors. Late last month Valeant stock came out with its quarterly confessional, which featured an improving and profitable bottom-line of 98-cents-per-share.
- InvestorPlace•5 months ago
Valeant Pharmaceuticals Intl Inc Stock Tumbles on Q4 Revenue Miss
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock took a hit today following the release of its earnings report for the fourth quarter of 2017. The big blow to VRX stock today was the company’s revenue of $2.16 billion for the fourth quarter of the year. It also came in below Wall Street’s revenue estimate of $2.18 billion for the quarter.
- InvestorPlace•5 months ago
Shopify Inc’s Problem Is It’s Still Not Making Money
It shows revenues of $222.8 million, nearly double the previous year’s $130 million, and a gross profit of $121 million. During my reporting career, I have seen several Canadian companies rise, and then fall, on their own hype.
- Reuters•11 months ago
Morning News Call Canadienne - Aout 8
Pour consulter la lettre d'information; cliquez sur le lien: http://share.thomsonreuters.com/assets/newsletters/Morning_News_Call/MNCCA_FR_08082017.pdf PRINCIPAUX INDICATEURS À L’AGENDA Pas d’indicateurs ...
